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LONG-TERM FOLLOWUP OF PATIENTS
#•
WITH SJOGREN’S SYNDROME
AIKE A. KRUIZE, RONALD J. HENÉ, AGNES v a n  d e r  HEIDE, BODEUTSCH,
PETER C. M. d e  WILDE, O. PAUL v a n  BIJSTERVELD, JAN d e  JONG, T. E. W. FELTKAMP,
LOUIS KATER, and JOHANNES W. J. BIJLSMA
Objective. To assess long-term outcome in pa­
tients with isolated keratoconjunctivitis sicca (KCS), 
primary Sjögren’s syndrome (SS), and secondary SS.
Methods. In 112 patients referred because of dry 
eyes, an ophthalmologic diagnosis of KCS was made 
based on results of the Schirmer I test, the tear fluid 
lysozyme concentration, and rose bengal staining. Sub­
sequent assessments, including sublabial salivary gland 
biopsy, were performed. Followup assessments were 
performed 10-12 years after initial diagnosis.
Results. Six patients were excluded because no 
biopsy specimen was available. Seventy-three percent of 
the remaining 106 patients were female, with a mean age 
of 53.5 years and a mean symptom duration of 3.9 
years. Application of the 1987 classification criteria of 
Daniels and Talal revealed a diagnosis of isolated KCS 
in 56 patients, primary SS in 31, and secondary SS in 
19. At baseline, 2 of 56 patients with isolated KCS and 
8 of 31 with primary SS exhibited mild features of organ- 
specific autoimmune disease. At followup, 2 of 38 pa­
tients with isolated KCS and 4 of 21 with primary SS 
had developed new features related to autoimmune 
disease, not necessitating treatment with corticosteroids; 
none of the patients developed major glandular compli­
cations. Three of 30 patients with primary SS died of
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malignant lymphoma. In 1 of these patients, the possi­
bility could not be excluded that sicca symptoms and 
infiltrates seen on sublabial salivary gland biopsy had 
occurred concomitantly with early stages of lymphoma. 
Malignant lymphoma did not develop in any of the 
patients with isolated KCS or secondary SS.
Conclusion. Primary Sjogren’s syndrome is char­
acterized by a stable and rather mild course of glandular 
and extraglandular manifestations, in marked contrast 
to the increased risk for development of malignant 
lymphoma in these patients. Since patients with isolated 
KCS do not have an increased risk for development of 
malignant lymphoma, a presumptive diagnosis of pri­
mary SS should be confirmed in patients with sicca 
syndrome.
Sjogren’s syndrome (SS) is an autoimmune 
exocrinopathy characterized by lymphoid infiltration 
and functional deterioration of exocrine glands, espe­
cially of lacrimal and salivary glands. SS mainly re­
sults in keratoconjunctivitis sicca (KCS) and xerosto­
mia, but extraglandular involvement may occur. SS 
may develop in the absence (primary SS) or in the 
presence (secondary SS) of another systemic autoim­
mune disease (1-6). The course of primary SS may be
by the of extraglandular
involvement and organ-specific autoimmune disease; 
discrepancies in reported frequencies of these compli­
cations possibly result from the different criteria used 
for the diagnosis of SS (1-6). Since the first report of 
an increased incidence of malignant lymphoma in 
patients with SS (7), multiple examples of this associ­
ation have been described, and primary SS is often 
considered to be a link between autoimmune and 
lymphoproliferative disease (4-8). Based on an epide­
miologic study, the risk of malignant lymphoma in 
patients with SS has been estimated to be ~6.4 cases 
per 1,000 per year
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In the present study we investigated outcome in 
patients with isolated KCS, patients with primary SS, 
and patients with secondary SS, 10-12 years after the 
initial diagnosis. We studied the development and 
complications of glandular disease and extraglandular 
manifestations, as well as the occurrence of lympho- 
proliferative disease in patients with primary SS and 
secondary SS. In patients with initial primary SS, we 
investigated for the development of rheumatoid arthri­
tis or other systemic autoimmune diseases.
PATIENTS AND METHODS
From 1976 through 1980, an ophthalmologic diagno­
sis of KCS was made in 112 patients who had been referred 
because of dry eyes. The diagnosis was based on results of 
the Schirmer I test, the tear fluid lysozyme concentration, 
and corneal and conjunctival staining with rose bengal dye 
(evaluated by slit lamp, and with estimation of the van 
Bijsterveld score) (9). Subsequent assessments included 
medical history and physical examination, as well as bio­
chemical and immunoserologic investigations. Sublabial sal-
■
ivary gland biopsies were performed according to the 
method of Greenspan (summarized in ref. 4). For long-term 
evaluation, we applied the criteria proposed in 1987 by 
Daniels and Talal (4,10,11) to the available data. SS-related 
KCS was thus defined by an abnormal rose bengal test result 
and reduced tear meniscus and break-up time, or an unanes­
thetized Schirmer test result <5 mm/5 minutes.
Followup assessments were performed 10-12 years 
after initial diagnosis. Patients who were not regularly seen 
at our outpatient department were traced with the help of 
their general practitioner or the Municipal Registry office. 
Medical history, physical examination, tear gland function 
tests, and biochemical and immunoserologic (antinuclear 
antibodies, anti-double-stranded DNA, and rheumatoid fac­
tor) investigations were repeated. A second sublabial sali­
vary gland biopsy was not obtained because of its invasive 
character. In order to determine the lymphocytic focus 
score, sublabial salivary gland biopsy specimens obtained at 
initial diagnosis were reviewed by 2 of the authors (CB and 
PCMdeW) (4,10). The more specific and sensitive quantita­
tive immunohistologic criteria to confirm the diagnosis of 
SS, based on percentages of IgA- and IgG-containing plasma 
cells, could not be used in this study: all sublabial salivary 
gland biopsy specimens had been fixed in buffered formol 
solution, thus making quantitative immunohistochemical in­
vestigation unreliable (12,13).
Six patients were excluded from the study because 
their sublabial salivary gland biopsy specimens were not 
available for review at followup. In 31 patients without 
another systemic autoimmune disease, review of the lip 
biopsy specimen revealed a focus score >1, i.e., more than 1 
focus of at least 50 lymphocytes/4 mm2, compatible with a 
diagnosis of primary SS. In 56 patients without another sys­
temic autoimmune disease, review of the sublabial salivary 
gland biopsy revealed a focus score <1; thus, the initial 
ophthalmologic diagnosis of KCS was maintained. In 19 pa­
tients with a focus score >  1, a diagnosis of secondary SS was 
made because of the presence of another connective tissue 
disease: rheumatoid arthritis in 11 patients, dermatomyositis 
in 2, systemic sclerosis in 4, and systemic lupus erythema­
tosus in 2. At followup, additional tests were performed, 
including testing for antibodies against extractable nuclear 
antigens (anti-RNP, anti-Sm, anti-Ro/SS-A, and anti-La/SS-B 
antibodies) determined by counterimmunoelectrophoresis, 
and anti-RNP, anti-Sm, anticentromere, anti-Scl-70, and 
anti-La/SS-B antibodies by HeLa cell immunoblotting.
Statistical analysis. To determine the statistical sig­
nificance of differences between the groups of patients with 
isolated KCS, primary SS, and secondary SS at study entry 
and at follow up, the chi-square test and the Kruskal-Wallis 
test were used for dichotomous and continuous variables, 
respectively. To determine the significance of differences 
between the groups with isolated KCS and primary SS and 
between the groups with primary SS and secondary SS at 
study entry, the chi-square test and the Mann-Whitney test 
were used for dichotomous and continuous variables, re­
spectively. The statistical significance of differences within 
patient groups at followup versus study entry was deter­
mined with the McNemar test and the Wilcoxon signed rank 
test for dichotomous and continuous variables, respectively.
RESULTS
Baseline findings. Baseline characteristics of the 
patients by group are shown in Table 1. In contrast to 
the 2 other patient groups, the primary SS group was 
almost exclusively female (93%, versus 58% in the 
secondary SS group and 66% in the isolated KCS 
group). Although the patients in the 3 groups reported 
dryness of the eyes with equal frequency, patients 
with secondary SS less often reported a sandy feeling 
in the eyes (.P <  0.05). Swelling of the parotid glands 
was noted particularly in patients with primary SS and 
secondary SS (P <  0.01), whereas myalgia and arthral­
gia were predominantly seen in patients with second­
ary SS (P < 0.05). Arthritis was observed only in 
patients with secondary SS and rheumatoid arthritis 
(P <  0.001). Raynaud’s phenomenon was reported in 
all 3 patient groups. A statistically significant differ­
ence in the results of tear gland function tests was 
noted between the 3 patient groups: in patients with 
primary SS, tear fluid lysozyme concentration, 
Schirmer I test, and the rose bengal test showed a 
significantly higher degree of deterioration than in 
patients with isolated KCS or secondary SS.
Statistically significant differences in terms of 
laboratory parameters were also seen: increased 
erythrocyte sedimentation rate (ESR) in patients with 
primary SS and secondary SS (P <  0.001) and de­
creased serum hemoglobin levels in patients with 
primary SS and secondary SS (P <  0.001) as compared
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Tabic 1. Baseline characteristics of the patients, by group
Females
Mean ±  SD age, years 
Mean ±  SD disease, years 
Dry eyes
Sandy feeling in eyes
Inflammatory reaction in eyes
Oral dryness
Oral infection
Subjective parotid swelling
Fatigue
Myalgia
Arthralgia
Raynaud’s phenomenon 
Objective parotid swelling
Splenomegaly
Neuropathy
Malignant lymphoma
Extraglandular disease
Antinuclear antibodies
Rheumatoid factor
Antithyroid antibodies
Antiparietal antibodies
Anti-smooth muscle antibodies
Antimitochondrial antibodies
Anti-salivary gland antibodies
Mean ±  SD tear lysozyme concentration, /ug/ml
Mean ± SD Schirmer test result, mm/5 minutes
Mean ±  SD rose bengal test
Mean ± SD ESR (Westergren), mm/hour
Mean ± SD serum hemoglobin, gm/dl
Mean ±  SD IgG, gm/liter
Mean ± SD IgM, gm/liter
Mean ± SD IgA, gm/liter
Isolated KCS 
(n = 56)
Primary SS 
(n = 31)
Secondary SS
(n 19) P
37 (66)t 29 (93) 11 (58)t 0.001 <  P < 0.01
50.7 ± 16.0 55.8 ± 13.2 58.2 ±  13.2
3.4 ±  3.6 5.4 ± 5.1 3.0 ± 2.6
51 (91) 28 (90) 15 (79)
47 (84) 25 (81) 10 (53)t 0.01 <  P < 0.05
16 (29) 12 (39) 2 (10)
39 (70) 28 (90) 16 (84)
2(4) 2(6) 1 (5)
0(0)t 14 (45) 5 (26) 0.001 <  P  <0.01
18 (32)t 15 (48) 6(32)
19 (34) 14 (45) 13 (68) 0.01 <  P < 0.05
18 (32) 12 (39) 13 (68) 0.01 <  P < 0.05
0(0) 0(0) 11 (58)t <0.001
9(16) 4(13) 4(21)
3(5) 6(19) 4(21)
0(0) 1 (3) 0(0)
0(0) 1 (3) 0(0)
0(0) 0(0) 0(0)
0(0) 1 (3) 0(0)
0(0) 0(0) 0(0)
2 (4)t 8 (26) 8(42) <0.001
1 (2)t 13 (42) 5 (26) <0.001
3 (5)t 15 (48) 5 (26) <0.001
3(5) 3 (10) 2(10)
0(0) 1(3) 0(0)
0(0) K3) 1(5)
0(0) 0(0) 1(5)
0(0) 2(6) 1 (5)
1,061 ± 7271 511 ± 308 1,066 ± 770t <0.001
9.9 ± 8.7t 4.5 ± 3.3 6.6 ± 5.0 0.001 <  P < 0.01
3.4 ± 2.Of 4.6 ± 1.7 3.0 ± 1.7t 0.001 < P <  0.01
11.8 ± 13.lt 38.5 ± 27.6 40.3 ± 27.6 <0.001
14.5 ± l . l f 13.2 ± 1.5 12.9 ± 2.3 <0.001
12.2 ±  3.3t 19.9 ± 8.7 15.8 ± 6.2 <0.001
1.5 ±  0.9 2.2 ± 2.8 3.0 ± 4.7
1.9 ±  0.7t 3.4 ± 1.9 3.0 ±  2.3 <0.001
* Except where otherwise indicated, values are the number (%). Normal values are are follows: tear lysozyme concentration ^ 1,400 Mg/ml; 
Schirmer test >5 mm/5 minutes; rose bengal test <3; erythrocyte sedimentation rate (ESR) 2-12 mm/hour; serum hemoglobin 11.9-17.2 gm/dl; 
serum IgG 6.83-11.17 gm/liter; serum IgM 0.86-1.78 gm/liter; serum IgA 0.89-1.99 gm/liter. KCS = keratoconjunctivitis sicca; SS =  Sjogren’s 
syndrome.
t P -  0.05 versus primary SS group.
S, whereas in patients with primary SS, serum ism (patients 1 and 2, Table 2). Among the patients
’Ci and IgA levels were significantly increased (P <  
0.001). Antinuclear antibodies and rheumatoid factor
autoimmune
ease was seen in 1 (patient 89, Table 2), whereas
were predominantly seen in patients with primary SS several patients expressed extraglandular manifesta-
or secondary SS (P <  0.001).
At study entry, 8 of 31 patients with primary SS 
exhibited extraglandular manifestations or organ-
autoimmune disease foatients 57-64, Table 2).
tions which could be attributed in part to the under-
autoimmune
One
and hepatomegaly, but no cause was found 
i extensive examination including laparotomy,
Findings at followup. In the primary SS group, I 
patient was unwilling to cooperate and 1 was lost to 
followup. Eight of 30 patients with primary SS had 
died at the time of the followup investigation; lym­
phoid malignancy was the cause of death in 3 (Table
and the findings proved to be transient. Of the patients 2). Of these 3 patients, 1 had developed a rapidly 
with isolated KCS, 1 exhibited vitiligo and primary progressive swelling of the left submandibular gland 
autoimmune hypothyroidism and 1 had hyperthyroid- and enlarged lymph nodes in the neck region within 2
300 KRUIZE ET AL
Table 2. Extraglandular and organ-specific autoimmune disease in patients with KCS, primary SS, and secondary SS at study entry and at 
followup, and overall mortality and mortality related to lymphoma at followup*
Group, Findings at Findings at
patient no. study entry followupt
Isolated KCS (n = 56, 38)
Patient 1 Vitiligo, primary autoimmune hypothyroidism NC
Patient 2 Hyperthyroidism NC
Patient 3 IgA nephropathy
Patient 4 — Antithyroid antibodies, euthyroidism
Patient 5 — Primary hypothyroidism, no antithyroid 
antibodies
Primary SS (n = 31, 21)
Death due to infectionPatient 57 Hepatomegaly ,$ lymphadenopathy$
Patient 58 Primary biliary cirrhosis NC
Patient 59 Primary autoimmune hypothyroidism NC
Patient 60 Primary autoimmune hypothyroidism RA
Patient 61 Vitiligo NC
Patient 62 Hyperviscosity syndrome^ IgMK paraproteinemia, peripheral neuropathy
Patient 63 Renal tubular acidosis, leukocytoclastic 
vasculitis (skin on legs)
NC
Patient 64 Mild renal dysfunction, pericarditis^ NC
Patient 65 Sclerodactyly, no anti-centromere or anti-SC 1-70 
antibodies, pernicious anemia, antiparietal 
antibodies
Patient 66 — Raynaud’s phenomenon
Patient 67 — Death due to lymphoma§
Patient 68 — Death due to lymphoma
Patient 69 — Death due to lymphoma
Secondary SS (n = 19, 12)
Secondary SS/RA (n =  11, 6)
Patient 87 Systemic vasculitis^ —
Patient 88 Pericarditis^ Cardiovascular disease
Patient 89 Primary autoimmune hypothyroidism Death due to cardiovascular disease
Patient 90 Cardiomyopathy Death due to cardiovascular disease
Secondary SS/DM (n = 2, 2)
Patient 98 Interstitial nephritis NC
Secondary SS/SSc (n = 4, 3)
Patient 100 IgA nephropathy NC
Patient 101 — Primary autoimmune hyperthyroidism
Secondary SS/SLE (n = 2, 1)
Patient 105 Bone marrow hypoplasia Cerebrovascular accident
Patient 106 Mixed type III cryoglobulinemia Death due to cardiovascular disease
* n values represent the totals at study entry and at followup, respectively. KCS = keratoconjunctivitis sicca; SS = Sjogren’s syndrome; NC 
= not changed; RA = rheumatoid arthritis; DM = dermatomyositis; SSc = systemic sclerosis.
t Mortality related to lymphoma was 0/53, and overall mortality was 10/53, in the group with isolated KCS. Mortality related to lymphoma was 
3/30 and overall mortality was 8/30 in the group with primary SS. Mortality related to lymphoma was 0/18 and overall mortality was 6/18 in the 
group with secondary SS.
$ Transient.
§ Lymphoma developed within 2 months of diagnosis (see Results).
months after primary SS was diagnosed; biopsy of 
the submandibular gland revealed a centroblastic/ 
centrocytic malignant lymphoma. Sicca symptoms had 
started 6-12 months before the diagnosis of primary 
SS was made. Her death may (arbitrarily) be consid­
ered not SS related because in retrospect, the possi­
bility cannot be excluded that the sicca symptoms as 
well as the infiltrates seen on sublabial salivay gland 
biopsy were due to early stages of lymphoma.
The second patient developed extreme fatigue 
and dizziness 3 years after study entry; further inves­
tigation revealed malignant lymphoma, i.e., immuno- 
blastic sarcoma located in the abdomen, bone, and 
cerebrum. In spite of treatment with cytostatic drugs, 
the patient died 2 years after the diagnosis of malignant 
lymphoma.
The third patient was admitted to the hospital 3 
years after study entry because of confluent hemor­
rhage of the skin of the abdomen, arms, and legs. 
Within 3 days she went into coma, a clinical diagno­
sis of intracerebral hemorrhage was made, and she 
subsequently died. Autopsy revealed polymorphic
Table 3. Differences in patient groups between baseline and followup*
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Iso ated KCS (n = 38) Primary SS (n = 21) Secondary SS (n = 12)
Baseline Followup Baseline Followup Baseline Followup
Dry eyes 33 (87) 30 (79) 19 (90) 19 (90) 9 (75) 9(75)
Sandy feeling in eyes 34 (89) 26 (68) t 19 (90) 15 (71) 7 (58) 4(33)
Inflammatory reaction in eyes 13 (34) 1 (3)* 9 (43) 2(9) 2 (17) 0(0)
Oral dryness 27 (71) 26 (68) 18 (86) 16 (76) 10 (83) 7 (58)
Oral infection I (3) 1 (3) 0 (0) 0(0) 1 (8) 0(0)
Subjective parotid swelling 4 (10) 1 (3) 7 (33) 4(19) 5 (42) 2(17)
Fatigue 15 (39) 14 (37) 8 (38) 9 (43) 4 (33) 7(58)
Myalgia 14 (37) 17 (45) 10 (48) 12 (57) 9 (75) 5 (42)
Arthralgia 12 (32) 17 (45) 8 (38) 9(43) 7 (58) 6(50)
Arthritis 0 (0) 0(0) 0 (0) 1 (1) 6 (50) 6 (50)
Raynaud’s phenomenon 7 (18) 4 (10) 3 (14) 4 (19) 2 (17) 2 (17)
Objective parotid swelling 2(5) 1 (3) 4 (19) 2(9) 4 (33) 2(17)
Lymphadenopathy 0(0) 0(0) 0 (0) 0 (0) 0 (0) 0(0)
Hepatomegaly 0(0) 0(0) 0 (0) 0(0) 0(0) 0(0)
Splenomegaly 0(0) 0(0) 0 (0) 0(0) 0(0) 0(0)
Neuropathy 1 (3) 1 (3) 0 (0) 0(0) 0(0) 0(0)
Lymphoma 0(0) 0(0) 0 (0) 0(0) 0(0) 0(0)
Antinuclear antibodies 0(0) 5 (13) 11 (52) 12 (57) 3 (25) 3 (25)
Anti-doubled-stranded DNA 0(0) 1 (3) 0 (0) 3 (14) 1 (8) 1 (8)
Rheumatoid factor 2(5) 5(13) 11 (52) 11 (52) 2(17) 4(33)
Antithyroid antibodies 2(5) 5 (13) 3 (14) 4 (19) 1 (8) 1(8)
Antiparietal antibodies 0(0) 1 (3) 1 (5) 1 (5) 0(0) 0(0)
Anti-smooth muscle antibodies 0(0) 2(5) 0 (0) 2 (10) 0(0) 0(0)
Antimitochondrial antibodies 0(0) 0(0) 0 (0) 1 (5) 0(0) 0(0)
Anti-salivary gland antibodies 0(0) 0(0) 1 (5) 2 (10) 1 (8) 1 (8)
Counterimmunoelectrophoresis 
Anti-RNP antibodies 0(0) 0(0) 0(0)
Anti-Sm antibodies — 0(0) — 0(0) — 0(0)
Anti-SS-A antibodies — 0(0) — 13 (62) — 1 (8)
Anti-SS-B antibodies — 0(0) _ 11 (52) — 0(0)
HeLa cell immunoblotting 
Anti-RNP antibodies 1 (3) 0(0) 0(0)
Anti-Sm antibodies — 1 (3) — 0(0) — 0(0)
Anticentromere antibodies — 1 (3) * 0(0) max» 1 (8)
Anti-Sc 1-70 antibodies — 1 (3) — 0(0) 1 (8)
Anti-SS-B antibodies •DM 6(16) « 9(43) — 2 (17)
Mean ± SD (Westergren), mm/hour 8.3 ± 5.7 11.5 ± 9.7t 37.8 ± 29.7 44.6 ±  37.8 31.1 ± 27.2 26.9 ±  18.9
Mean ± SD serum hemoglobin, gm/dl 14.5 ± 1.0 14.3 ± 1.0 13.4 ± 1,5 13.2 ± 1.5 12.9 ± 2.3 13.7 ± 2.3
Mean ± SD IgG, gm/liter 12.1 ± 3.4 11.6 ± 3.5 19.9 ± 8.1 16.9 ± 6 .1 t 16.0 ± 6.6 14.6 ± 5.1
Mean ± SD IgM, gm/liter 1.5 ± 0.9 1.5 ± 0.9 2.5 ± 3 .4 2.7 ± 4.1 2.2 ± 3.0 1.4 ± 0.6
Mean ± SD IgA, gm/liter 2.0 ± 0.7 2.2 ± 0.9t 3.6 ± 2.2 3.5 ± 1.6 2.4 ± 1.4 2.6 ± 1.7
* Except where otherwise indicated, values are the number (%). See Table 1 for definitions and for normal values.
t 0.01 <  P <  0.05, versus baseline. 
:|: P <  0.001 versus baseline.
immunocytoma in liver, , and abdominal
lymph nodes; furthermore, extensive hemorrhagic di­
athesis and diffuse intravascular coagulation were 
noted.
Among the remaining 21 patients with primary 
SS who were available at the time of followup, 4 had 
developed new features of autoimmune disease (pa­
tients 60, 62, 65, and 66; Table 2). Within the primary 
SS patient group, no statistically significant differences 
in symptoms and signs between baseline and followup 
were noted, apart from the observation that patients
with primary SS did not experience as much inflam­
matory reaction of the eyes at followup (P < 0.05)
(Table 3). No statistically significant differences in 
laboratory parameters were noted except for a de­
crease in the mean serum IgG level (P < 0.05) 
(Table 3).
Six of the patients with secondary SS had died 
at followup, but none of the deaths was due to lym­
phoid malignancy; 1 patient in the secondary SS group 
was unwilling to cooperate. Among the remaining 12 
patients available at followup, 1 patient with second-
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ary SS and systemic sclerosis had developed primary 
autoimmune hyperthyroidism (patient 101, Table 2). 
No statistically significant differences in symptoms 
and signs or in laboratory parameters between study 
entry and foliowup were noted in this group (Table 3).
In the KCS group, 3 patients were lost to 
followup and 5 were unwilling to cooperate. Ten of 53 
patients with KCS had died; none had died of malig­
nant lymphoma. Among the 38 patients with KCS 
available at followup, 2 had developed features possi­
bly related to autoimmune disease (patients 4 and 5, 
Table 2). At followup, the proportion of KCS patients 
who experienced a sandy feeling in the eyes (.P <  0.05) 
or an inflammatory reaction of the eyes (P <  0.001) 
was lower than at baseline (Table 3). No further 
differences in symptoms and signs between study 
entry and followup were noticed.
Regarding differences in laboratory parameters 
in the 3 patient groups at followup, anti-Ro/SS-A and 
anti-La/SS-B antibodies (by counterimmunoelectro- 
phoresis) were present predominantly in patients with 
primary SS and were absent in patients with KCS (P <  
0.001); anti-La/SS-B antibodies determined by HeLa 
cell immunoblotting were present in all 3 patient
groups (P >  0.05) (Table 3). Statistically significant 
differences between the 3 patient groups at followup
were noted for the ESR (P <  0.001) and for serum 
hemoglobin (P <  0.05), IgG (P < 0.01), and IgA (P <  
0.05) levels.
DISCUSSION
In this report we have described the long-term 
course in a group of 112 patients initially referred to 
our ophthalmology department because of KCS. 
Based on application of the classification criteria as 
proposed by Daniels and Talal, 50 of these patients 
appeared to have SS. When applying the proposed 
European Economic Community criteria (14) to the 
data available at followup, 2 of 38 KCS patients 
without positive lip biopsy results and all primary SS 
and secondary SS patients would fulfill these criteria 
(results not shown). At baseline, 2 of 56 patients with 
isolated KCS (4%) had features possibly related to 
autoimmune disease, while 8 of 31 patients with pri­
mary SS (26%) and 8 of 19 patients with secondary SS 
(42%) had extraglandular or organ-specific auto-
immune disease (P <  0.001) (Table 2), not necessitat­
ing treatment with corticosteroids in any of the pa­
tients. This rather mild character of SS at the time of 
inclusion in the study is comparable with that reported
in previous studies (1-3,15), despite differences in the 
selection of patients and in the classification criteria 
used.
At followup, 4 of 21 patients with primary SS 
(19%) had developed new features of autoimmune 
disease, including benign paraproteinemia, peripheral 
neuropathy, sclerodactyly, and Raynaud’s phenome­
non (Table 2). Since the prevalence of RA approaches 
1.0% in most reported series of Caucasian subjects 
(16), it can be questioned whether the development of 
RA meeting the American College of Rheumatology 
(formerly, the American Rheumatism Association) cri­
teria (17) in 1 patient with primary SS should be 
considered remarkable. No distinctive predictive 
value of any laboratory parameter assessed at study 
entry, with regard to prediction of the development of 
extraglandular manifestations, could be determined, 
possibly because of the stable course of the disease. 
Apart from the development of new extraglandular 
manifestations in 4 patients, the absence of major 
differences within the primary SS patient group be­
tween study entry and followup is consistent with our 
clinical observation of absence of major exacerbations 
and remissions of disease activity in primary SS. In 
contrast to the demonstration in previous studies of 
severe extraglandular features of autoimmune disease 
necessitating corticosteroid treatment (4-6), the extra­
glandular manifestations in our population with pri­
mary SS can be considered mild.
The observation that none of the patients with 
isolated KCS or secondary SS had developed lympho- 
proliferative disease confirms the suggestion that it is 
primary SS in particular which gives rise to an in­
creased risk for the development of lymphoprolifera- 
tive disorders. At followup, 3 of 30 patients with
primary SS died of malignant lymphoma. In 1
patient, the possibility that sicca symptoms as well as 
infiltrates seen on sublabial salivary gland biopsy were 
due to early stages of lymphoma cannot be excluded. 
One other patient had developed benign IgMx para­
proteinemia. Covering a total of ~480 person-years 
from the start of symptoms as recorded in the medical 
history (310 person-years from the time of diagnosis of 
primary SS) in the primary SS patient group, these 
findings are broadly compatible with those reported in 
a study by Kassan and coworkers (8).
The patients with primary SS and secondary SS 
in our series may represent a subgroup of SS patients, 
since all initially had been referred to an ophthalmol­
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ogy department because of dry eyes. Apart from the 
marked risk for development of malignant lymphoma, 
necessitating clinical followup of the individual patient 
on a regular basis, our findings show that primary SS is 
characterized by a stable and relatively mild course. 
Since patients with isolated KCS do not have an 
increased risk for development of malignant lym­
phoma, a presumptive diagnosis of primary SS should 
be confirmed in order to determine the necessity of 
long-term medical monitoring.
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